FIELD: chemistry.
SUBSTANCE: invention relates to molecular pharmacology and specifically to a peptide which is part of an interleukine-15 (IL-15) sequence which can inhibit biological activity of the said molecule.
EFFECT: obtaining a peptide which inhibits T cell proliferation induced by IL-15, and apoptosis caused by tumour necrosis factor when bonding with the alpha subunit of the (IL-15R) receptor.
8 cl, 4 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INTERLEUKIN-15 ANTAGONIST PEPTIDE | 2009 |
|
RU2506270C2 |
| COMPOSITIONS AND METHOD FOR IMMUNOSUPPRESSION | 2001 |
|
RU2270691C2 |
| VACCINE COMPOSITION CONTAINING MUTANT HUMAN INTERLEUKIN-15 | 2017 |
|
RU2745199C2 |
| MODULATION OF IL-5 AND IL-MEDIATED CELL RESPONSES | 2001 |
|
RU2280255C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
| HETERODIMERIC IL-15 PROTEIN AND USE THEREOF | 2014 |
|
RU2689717C2 |
| RECOMBINANT CHIMERIC PROTEIN ANTH1, NUCLEIC ACID ENCODING ITS AND THEIR USING | 2003 |
|
RU2322455C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-R[ALPHA] SUSHI DOMAIN | 2012 |
|
RU2644671C2 |
| INTERLEUKIN 15 PROTEIN COMPLEX AND USE THEREOF | 2015 |
|
RU2711979C2 |
| APOPTOTIC ANTIBODIES AGAINST IgE | 2008 |
|
RU2500686C2 |
